Wischik, Claude MStaff, Roger TWischik, Damon JBentham, PeterMurray, Alison DStorey, John M DKook, Karin AHarrington, Charles R2015-01-272015-01-272015-01-22Wischik, C M, Staff, R T, Wischik, D J, Bentham, P, Murray, A D, Storey, J M D, Kook, K A & Harrington, C R 2015, 'Tau Aggregation Inhibitor Therapy : An Exploratory Phase 2 Study in Mild or Moderate Alzheimer's Disease', Journal of Alzheimer's Disease, vol. 44, no. 2, pp. 705-720. https://doi.org/10.3233/JAD-1428741387-2877ORCID: /0000-0002-5261-5467/work/73579154ORCID: /0000-0003-4915-4847/work/44018599ORCID: /0000-0003-2250-3920/work/47672911http://hdl.handle.net/2164/4205ACKNOWLEDGMENTS We thank patients and their caregivers for their participation in the study and are indebted to all the investigators involved in the study, particularly Drs. Douglas Fowlie and Donald Mowat for their helpful contributions to the clinical execution of the study in Scotland. We thank Sharon Eastwood, Parexel, for assistance in preparing initial drafts of the manuscript. We acknowledge constructive comments provided by Professors G. Wilcock and S. Gauthier on drafts of the article. CMW, CRH, and JMDS are officers of, and hold beneficial interests in, TauRx Therapeutics. RTS, PB, KK, and DJW are paid consultants to TauRx Therapeutics. The study was financed entirely by TauRx Therapeutics16630170engAlzheimer's diseasecontrolled clinical trialintervention studiesmethylthioniniumsafetytau proteinR MedicineSupplementary DataRJournal article10.3233/JAD-142874442